The full-length recombinant GGF2 isoform of NRG-1β is a growth factor which has being explored as a potential therapy for HF in several clinical trials (Brittain et al., 2013; Lenihan et al., 2013). This evidence concerns the gene NRG1 and hydrops fetalis.